Documentos relacionados

1. Overall and complete response rates as potential surrogates for overall survival in relapsed/refractory multiple myeloma.
2. Mezigdomide and Multiple Myeloma.
3. Current Novel Targeted Therapeutic Strategies in Multiple Myeloma.
4. ABL1 kinase plays an important role in spontaneous and chemotherapy-induced genomic instability in multiple myeloma.
5. New Biological Therapies for Multiple Myeloma.
6. Talquetamab in multiple myeloma.
7. BCMA- or GPRC5D-targeting bispecific antibodies in multiple myeloma: efficacy, safety, and resistance mechanisms.
8. Plain language summary of the MajesTEC-1 study of teclistamab for the treatment of people with relapsed or refractory multiple myeloma.
9. Teclistamab-cqyv in multiple myeloma.
10. Patient perspectives on considerations, tradeoffs, and experiences with multiple myeloma treatment selection: a qualitative descriptive study.